CORRIA OSORIO, ANGEL DE JESUS ADJ,LEON MONZON, KALET K,CARMENATE PORTILLA, TANIA T,PUPO MERINO, AMAURY A,PEREZ RODRIGUEZ, SAUMEL S,.科裡亞奧索裡奧,.裡昂蒙松,.卡爾梅納特波蒂利亞,.普波梅裡諾,.佩雷斯羅德裡格斯
申请号：
HK16101766.2
公开号：
HK1213781A
申请日:
2016.02.18
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF² molecule whose primary sequence has a high homology with the sequence of human TGF². These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T²RII and T²RIII). They have the property of antagonizing the signaling of all natural variants of TGF² ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.
